High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC
Introduction Despite significant successes, immune checkpoint blockade fails to achieve clinical responses in a significant proportion of patients, predictive markers for responses are imperfect and immune-related adverse events (irAEs) are unpredictable. We used T-cell receptor (TCR) sequencing to...
Saved in:
Main Authors: | Alexandre Reuben, Mehmet Altan, Latasha Little, Jianjun Zhang, Ajay Sheshadri, Hai T Tran, Mara B Antonoff, Stephen G Swisher, John V Heymach, Saumil Gandhi, Natalie Vokes, Ziyi Li, Ruoxing Li, Runzhe Chen, Joshua Baguley, Jefferson Sinson, Greg Lizee |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-12-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/12/12/e008950.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of Immune Checkpoint Inhibitors and Local Radical Treatment on Survival Outcomes in Synchronous Oligometastatic NSCLC
by: Mandy Jongbloed, MD, et al.
Published: (2025-03-01) -
The effect of baseline versus early glucocorticoid use on immune checkpoint inhibitor efficacy in patients with advanced NSCLC
by: Yifan Wang, et al.
Published: (2025-01-01) -
Immune Checkpoint Inhibitors +/− Chemotherapy for Patients With NSCLC and Brain Metastases: A Systematic Review and Network Meta‐Analysis
by: Lauren Julia Brown, et al.
Published: (2025-01-01) -
Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
by: David P Carbone, et al.
Published: (2023-01-01) -
Characterization of the genomic landscape in liver oligometastatic NSCLC
by: Rongxin Liao, et al.
Published: (2025-01-01)